Hepatitis D screening

Revision as of 12:12, 6 August 2014 by Joao Silva (talk | contribs)
Jump to navigation Jump to search

Hepatitis Main Page

Hepatitis D

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Hepatitis D from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis D screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis D screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis D screening

CDC on Hepatitis D screening

Hepatitis D screening in the news

Blogs on Hepatitis D screening

Directions to Hospitals Treating Hepatitis D

Risk calculators and risk factors for Hepatitis D screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Jolanta Marszalek, M.D. [3]

Overview

Screening

All patients with current or previous IV drug use history should be evaluated for hepatitis B. However, screening is not recommended in asymptomatic HBsAg positive patients. Preventive measures and screening may be applied in:

  • HBsAg positive patients, who have acute or chronic hepatitis D. The follow-up procedures should be equal, regardless of co-infection status with hepatitis D
  • Patients who have acute hepatitis B, are not HBsAg positive and who are IgM anti-HBc positive may be tested for HDV.
  • Patients with positive HBsAg and/or HDV antibody should be alerted not to share items such as razors, eating or drinking utensils.
  • Patients without immunity to the virus should be vaccinated.

The general population, without risk for HBV and /or HDV, does not need screening.

Attending to the life cycle of HDV, and the potential complications of infection with this virus, the following screening recommendations should be applied:

[1]

[1]

[1]

Blood products should also be screened for the presence of HDV and HBV, to prevent infection by blood transfusion and hemodialysis.[2]

References

  1. 1.0 1.1 1.2 Lok AS, McMahon BJ (2004). "[AASLD Practice Guidelines. Chronic hepatitis B: update of therapeutic guidelines]" (PDF). Romanian Journal of Gastroenterology. 13 (2): 150–4. PMID 15229781. Retrieved 2012-02-10. Unknown parameter |month= ignored (help)
  2. Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.

Template:WH Template:WS